432 related articles for article (PubMed ID: 26523025)
1. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
[TBL] [Abstract][Full Text] [Related]
2. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
3. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
4. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term clinical remission in rheumatoid arthritis.
Fornaro M; Cacciapaglia F; Lopalco G; Venerito V; Iannone F
Eur J Clin Invest; 2021 Feb; 51(2):e13363. PubMed ID: 32725883
[TBL] [Abstract][Full Text] [Related]
7. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.
Schlager L; Loiskandl M; Aletaha D; Radner H
Rheumatology (Oxford); 2020 Feb; 59(2):324-334. PubMed ID: 31325305
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
9. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
Tang CH; Yu F; Huang CY; Chen DY
Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
[TBL] [Abstract][Full Text] [Related]
10. Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission.
Kameda H; Hirata A; Katagiri T; Takakura Y; Inoue Y; Takenaka S; Ito H; Mizushina K; Ogura T
Sci Rep; 2021 Mar; 11(1):6865. PubMed ID: 33767314
[TBL] [Abstract][Full Text] [Related]
11. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
[TBL] [Abstract][Full Text] [Related]
12. Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study.
Vittecoq O; Desouches S; Kozyreff M; Nicolau J; Pouplin S; Rottenberg P; Sens N; Lequerre T; Avenel G
BMJ Open; 2019 Dec; 9(12):e031467. PubMed ID: 31857303
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled.
Kawashiri SY; Fujikawa K; Nishino A; Okada A; Aramaki T; Shimizu T; Umeda M; Fukui S; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Mizokami A; Nakamura H; Origuchi T; Ueki Y; Aoyagi K; Maeda T; Kawakami A
Arthritis Res Ther; 2017 May; 19(1):108. PubMed ID: 28545509
[TBL] [Abstract][Full Text] [Related]
14. Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis.
Komiya T; Takase-Minegishi K; Sakurai N; Nagai H; Hamada N; Soejima Y; Sugiyama Y; Tsuchida N; Kunishita Y; Kishimoto D; Kobayashi K; Kamiyama R; Yoshimi R; Kirino Y; Ohno S; Nakajima H
Int J Rheum Dis; 2019 Nov; 22(11):2009-2016. PubMed ID: 31515933
[TBL] [Abstract][Full Text] [Related]
15. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.
Ye W; Tucker LJ; Coates LC
Drugs; 2018 Nov; 78(16):1705-1715. PubMed ID: 30341684
[TBL] [Abstract][Full Text] [Related]
16. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs.
Valor L; Garrido J; Martínez-Estupiñán L; Hernández-Flórez D; Janta I; López-Longo FJ; Monteagudo I; González CM; Naredo E
Rheumatol Int; 2018 Aug; 38(8):1465-1470. PubMed ID: 29915991
[TBL] [Abstract][Full Text] [Related]
17. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
[TBL] [Abstract][Full Text] [Related]
18. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
[TBL] [Abstract][Full Text] [Related]
19. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
[TBL] [Abstract][Full Text] [Related]
20. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
